SONN Sonnet BioTherapeutics Holdings, Inc.

SONNET BioTherapeutics, Inc. is a biotechnology company that engages in development of bi and tri functional therapies that can simulate or block immune-modulating targets to control cancer. The company uses albumin binding single chain antibody fragment (scFv) for delivery of recombinant human-cytokines (rH-cytokines) and other validated targets. SONNET BioTherapeutics, Inc. was incorporated in 2015 and is based in Princeton, New Jersey.

As of 05/07/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  10/04/2019
Outstanding shares:  17,555,928
Average volume:  1,681,806
Market cap:   $29,669,518
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    83548R105
ISIN:        US83548R1059
Sedol:      BKSG5G0
Valuation   (See tab for details)
PE ratio:   -14.59
PB ratio:   -11.43
PS ratio:   5.22
Return on equity:   788.10%
Net income %:   -345.03%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy